Kura Oncology Inc   (KURA)
Other Ticker:  
Price: $21.4900 $0.32 1.512%
Day's High: $21.75 Week Perf: -2.8 %
Day's Low: $ 21.09 30 Day Perf: 9.36 %
Volume (M): 436 52 Wk High: $ 24.17
Volume (M$): $ 9,378 52 Wk Avg: $14.10
Open: $21.49 52 Wk Low: $7.41

 Market Capitalization (Millions $) 1,660
 Shares Outstanding (Millions) 77
 Employees 66
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -143
 Cash Flow (TTM) (Millions $) -62
 Capital Exp. (TTM) (Millions $) 0

Kura Oncology Inc
Kura Oncology Inc is a publicly-traded biopharmaceutical company headquartered in La Jolla, California. The company is focused on developing innovative medicines for the treatment of cancer. Kuraes lead drug candidate, tipifarnib, is a selective farnesyltransferase inhibitor, which inhibits a critical enzyme in the Ras pathway, and has shown promising results in various clinical trials.

The company was founded in 2014 by Troy Wilson and Yi Liu. It raised $60 million in its initial public offering in 2015, and since then has continued to raise additional capital through secondary offerings and collaborations. As of 2021, Kura has a market capitalization of over $1 billion.

Kura is focused on developing drugs that target various cancer indications, particularly those with high unmet medical needs. The companyes pipeline includes several promising drug candidates in various stages of development, including KRA inhibitor, Kura-009, which is in Phase I clinical trials for the treatment of solid tumors with K-Ras mutations, and Menin-MLL inhibitor, KO-539, which is in preclinical development for the treatment of patients with leukemias and several other hematologic malignancies.

The companyes lead drug candidate, tipifarnib, has the potential to be a game-changer in the treatment of hematologic malignancies, particularly in acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Tipifarnib has already been granted fast track designation by the FDA, and its ongoing phase II clinical trials are showing promising results. The drug has also shown potential in treating other indications such as advanced head and neck cancer and peripheral T-cell lymphoma.

Kuraes scientific team consists of experts in drug discovery, preclinical evaluation, clinical development, and regulatory affairs. The company has a collaborative approach and works closely with academic institutions, clinical investigators, and industry partners, making it a leading player in the field of oncology drug development.

In summary, Kura Oncology Inc is a fast-growing biopharmaceutical company that is committed to developing innovative drugs for the treatment of cancer, particularly hematologic malignancies. The companyes pipeline of drug candidates, led by the promising tipifarnib, has the potential to revolutionize cancer treatment and improve the lives of patients suffering from cancer.

   Company Address: 12730 High Bluff Drive San Diego 92130 CA
   Company Phone Number: 500-8800   Stock Exchange / Ticker: NASDAQ KURA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Unlocking New Horizons: Promising Combinations of KO-2806 in Renal Cell Carcinoma and KRAS G12C-Mutant NSCLC Treatment

Published Wed, Mar 6 2024 12:30 PM UTC

Combining KO-2806 and Cabozantinib Shows Promise in Renal Cell Carcinoma Treatment, Upcoming Trials to Test KO-2806 with Adagrasib in KRAS G12C-Mutant NSCLCRenal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) are two prevalent types of cancer worldwide, with limited treatment options for advanced stages. However, recent studies by Kura Oncology have shown promis...

Financing Agreement

Kura Oncology Grants Inducement Awards to New Employees in Compliance with Nasdaq Rule 5635(c)(4)

Published Fri, Mar 1 2024 10:00 PM UTC

Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, recently announced the granting of inducement awards to two new employees. The Compensation Committee of the company's Board of Directors approved the issuance of nonstatutory stock options to purchase 93,000 shares of common stock as part of the 2023 Ind...

Clinical Study

Revolutionary Breakthrough: Kura Oncology's Ziftomenib Trial Offers New Hope for Acute Myeloid Leukemia Patients

Published Mon, Feb 26 2024 12:30 PM UTC

Kura Oncology Takes Promising Step Forward in Combating Acute Myeloid Leukemia In a groundbreaking development, Kura Oncology has administered the first patient with a potentially life-changing drug, ziftomenib, as part of the KOMET-008 clinical trial. The trial aims to evaluate the efficacy and safety of ziftomenib in combination with various standard treatments, including ...


Kura Oncology Empowers Talent with Inducement Awards Amidst Successful Private Placement Funding

Published Fri, Feb 2 2024 12:30 PM UTC

In the latest press release, Kura Oncology, a leading clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, announced the granting of inducement awards to three new employees. This strategic move emphasizes the company's commitment to fostering exceptional talent within the organization. Additionally, the company's...


Kura Oncology Secures $150 Million in Oversubscribed Private Placement Financing, Demonstrating Strong Investor Support and Confidence in Precision Medicines Approach

Published Wed, Jan 24 2024 12:01 PM UTC

Kura Oncology Announces Oversubscribed $150 Million Private Placement
Kura Oncology Inc, a leading precision medicines company, recently revealed that it has successfully closed an oversubscribed $150 million private placement financing round. The funding round was made possible with significant contributions from existing investors, including EcoR1 Capital, an affiliate...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com